Veracyte, Inc. (VCYT) on Decifer

Decifer ranks VCYT number 85 of 277 tracked names on durable business quality.

Why it ranks here

• Its returns on invested money are modest, around 5% and those returns have been improving and it turns most of its profit into real cash.
• Revenue is growing about 16% a year and profits grew 162% over the past year.
• It keeps a high share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power, with profitability widening as it grows.
• and has the balance sheet to fund its growth.
• We do not have a clean read on how it is run yet.
• Revenue up about 16% a year, profits up 162%, and momentum of 30 out of 35 are healthy, but modest 5% returns, an unclear read on management, and no worldview role cap it.

The current read

The evidence on VCYT lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• Healthcare, Biotech & Devices: Veracyte, Inc. operates in medical - diagnostics & research. That places it inside the Healthcare, Biotech & Devices story.

Read the full VCYT research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.